308 related articles for article (PubMed ID: 35427197)
1. The eIg technology to generate Ig-like bispecific antibodies.
Kühl L; Aschmoneit N; Kontermann RE; Seifert O
MAbs; 2022; 14(1):2063043. PubMed ID: 35427197
[TBL] [Abstract][Full Text] [Related]
2. Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules.
Seifert O; Rau A; Beha N; Richter F; Kontermann RE
MAbs; 2019 Jul; 11(5):919-929. PubMed ID: 30951400
[TBL] [Abstract][Full Text] [Related]
3. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
4. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
5. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
6. Constant domain-exchanged Fab enables specific light chain pairing in heterodimeric bispecific SEED-antibodies.
Dietrich S; Gross AW; Becker S; Hock B; Stadlmayr G; Rüker F; Wozniak-Knopp G
Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140250. PubMed ID: 31295556
[TBL] [Abstract][Full Text] [Related]
7. EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies.
Cooke HA; Arndt J; Quan C; Shapiro RI; Wen D; Foley S; Vecchi MM; Preyer M
MAbs; 2018; 10(8):1248-1259. PubMed ID: 30215570
[TBL] [Abstract][Full Text] [Related]
8. A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3.
Rau A; Kocher K; Rommel M; Kühl L; Albrecht M; Gotthard H; Aschmoneit N; Noll B; Olayioye MA; Kontermann RE; Seifert O
MAbs; 2021; 13(1):1902034. PubMed ID: 33752566
[TBL] [Abstract][Full Text] [Related]
9. A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain.
Schoonjans R; Willems A; Schoonooghe S; Leoen J; Grooten J; Mertens N
Biomol Eng; 2001 Jun; 17(6):193-202. PubMed ID: 11337278
[TBL] [Abstract][Full Text] [Related]
10. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
[TBL] [Abstract][Full Text] [Related]
11. A novel efficient bispecific antibody format, combining a conventional antigen-binding fragment with a single domain antibody, avoids potential heavy-light chain mis-pairing.
Huang S; Segués A; Hulsik DL; Zaiss DM; Sijts AJAM; van Duijnhoven SMJ; van Elsas A
J Immunol Methods; 2020 Aug; 483():112811. PubMed ID: 32569598
[TBL] [Abstract][Full Text] [Related]
12. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.
Wu X; Sereno AJ; Huang F; Zhang K; Batt M; Fitchett JR; He D; Rick HL; Conner EM; Demarest SJ
MAbs; 2015; 7(2):364-76. PubMed ID: 25611120
[TBL] [Abstract][Full Text] [Related]
13. The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity.
Seifert O; Plappert A; Heidel N; Fellermeier S; Messerschmidt SK; Richter F; Kontermann RE
Protein Eng Des Sel; 2012 Oct; 25(10):603-12. PubMed ID: 22988132
[TBL] [Abstract][Full Text] [Related]
14. Bispecific antibodies with Fab-arms featuring exchanged antigen-binding constant domains.
Benedetti F; Stracke F; Stadlmayr G; Stadlbauer K; Rüker F; Wozniak-Knopp G
Biochem Biophys Rep; 2021 Jul; 26():100959. PubMed ID: 33718630
[TBL] [Abstract][Full Text] [Related]
15. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
16. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
[TBL] [Abstract][Full Text] [Related]
17. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.
Aschmoneit N; Kühl L; Seifert O; Kontermann RE
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782429
[TBL] [Abstract][Full Text] [Related]
18. Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system.
Xu Y; Lee J; Tran C; Heibeck TH; Wang WD; Yang J; Stafford RL; Steiner AR; Sato AK; Hallam TJ; Yin G
MAbs; 2015; 7(1):231-42. PubMed ID: 25427258
[TBL] [Abstract][Full Text] [Related]
19. Influence of the bispecific antibody IgG subclass on T cell redirection.
Kapelski S; Cleiren E; Attar RM; Philippar U; Häsler J; Chiu ML
MAbs; 2019; 11(6):1012-1024. PubMed ID: 31242061
[TBL] [Abstract][Full Text] [Related]
20. eIg-based bispecific T-cell engagers targeting EGFR: Format matters.
Kühl L; Schäfer AK; Kraft S; Aschmoneit N; Kontermann RE; Seifert O
MAbs; 2023; 15(1):2183540. PubMed ID: 36864566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
